Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4

Sellas Life Sciences (SLS) was in the spotlight on Wednesday after the biotech firm said it will present Phase 2 results for its experimental blood cancer treatment SLS009 at the…

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (stocktwits.com)